| Trial ID: | L0433 |
| Source ID: | NCT02608177
|
| Associated Drug: |
Linagliptin
|
| Title: |
Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management
|
| Acronym: |
CANDY-CANE
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT02608177/results
|
| Conditions: |
Chronic Kidney Diseases|Type 2 Diabetes
|
| Interventions: |
DRUG: Linagliptin|DRUG: Glipizide
|
| Outcome Measures: |
Primary: Glucose Time in Range, Time with glucose 70-140 mg/dL, last 6 days of each 28-day treatment period | Secondary: Glycemic Variability, SD of glucose readings, last 6 days of each 28-day treatment period|Hypoglycemia, Glucose \<70 mg/dL for at least 10 minutes, last 6 days of each 28-day treatment period|Biomarkers of Systemic Inflammation, Measured by plasma C-reactive protein (CRP), last 6 days of each 28-day treatment period|Biomarkers of Systemic Inflammation, Measured by plasma interleukin-6, last 6 days of each 28-day treatment period|Biomarkers of Oxidative Stress, Measured by plasma F2-isoprostanes, last 6 days of each 28-day treatment period|Biomarkers of Oxidative Stress, Measured by urine F2-isoprostanes, last 6 days of each 28-day treatment period|Biomarkers of Albuminuria, Measured by albumin-creatinine ratio, last 6 days of each 28-day treatment period
|
| Sponsor/Collaborators: |
Sponsor: University of Washington | Collaborators: American Diabetes Association|Medtronic|Abbott
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
3
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2015-11
|
| Completion Date: |
2018-08
|
| Results First Posted: |
2018-09-13
|
| Last Update Posted: |
2018-10-12
|
| Locations: |
University of Washington, Seattle, Washington, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT02608177
|
